Introduction
============

Prostate cancer (PCa) is one of the most common non-cutaneous malignancies among men in developed country, with an estimated 161,360 new cases and 26,730 deaths in the United States in 2017 [@B1]. Many influencing factors have been proved to be associated with the risk of PCa, including advancing age, ethnicity, smoking and alcohol consumption, endocrine system, and genetic factors. However, the underlying etiology of PCa is still confusing [@B2]. Recently, genetic predisposition of PCa have gradually attracted investigators\' attention. Especially, it suggested that common genetic polymorphisms such as single nucleotide polymorphic variants (SNPs) might be associated with sporadic cases of PCa [@B3]. In addition, several studies have identified the 8q24 polymorphisms increased the risk of PCa [@B4]-[@B6]. Therefore, we plan to study the etiology of PCa from the aspect of genetic predisposition.

Chromosomal region 8q24 has been proved to be associated with a wide spectrum of cancers, including cancers of the breast, prostate, bladder, colon, lung, ovaries and pancreas among different ethnicities [@B7]-[@B13]. A region on chromosome 8q24 was originally shown to confer PCa risk in a genome-wide linkage scan of 871 Icelandic men in 2006 [@B14]. In addition, 8q24 was considered as a gene-free region, flanked by the FAM84B and MYC genes on the centromeric and telomeric ends respectively [@B15]. Physical nearness might indicate the association between 8q24 and MYC proto-oncogene. As a highly conserved genomic region, three 8q24 regions (region 1: 128.54-128.62 Mb; region 2: 128.12-128.28 Mb; region 3: 128.47-128.54 Mb) have been identified to contain variants independently associated with PCa susceptibility [@B16]. Subsequently, multiple independent studies have been performed to extensively explore the roles of 8q24 SNPs in the risk of PCa. Thus, it was hypothesized that the genetic variations in the 8q24 region were likely to take effect in prostate carcinogenesis.

Genome-wide association studies (GWAS) have identified more than 100 common SNPs that were associated with the susceptibility of PCa. A large number of studies have explored the associations between these polymorphisms and the risk of PCa [@B17]. In previous studies, five 8q24 polymorphisms (rs6983267 T\>G, rs1447295 C\>A, rs16901979 C\>A, rs6983561 A\>C and rs10090154 C\>T) among these SNPs might have strong associations with PCa susceptibility. Nevertheless, the results of these studies were inconsistent and inconclusive [@B4],[@B18]-[@B20]. Hence, we conducted an updated meta-analysis including all eligible case-control studies to investigate the association between 8q24 gene polymorphisms and the risk of PCa.

Materials and Methods
=====================

We searched PubMed, EMBASE, Web of Science and Wan Fang databases comprehensively to obtain relevant studies published up to February 1^st^, 2017. The following searching keywords were utilized: "8q24", "polymorphisms" or "mutations" or "variants", and "prostate cancer" or "prostatic neoplasms". Potential eligible articles were manually collected by searching from the reference lists of relevant literature and reviews. In addition, overlapping data from different articles were removed.

Then, all eligible articles were collected according the following inclusive criteria: (1) Independent case-control or cohort studies; (2) Possessing at least one of 8q24 polymorphisms (rs6983267 T\>G, rs1447295 C\>A, rs16901979 C\>A, rs6983561 A\>C and rs10090154 C\>T); (3) Availability of genotype data of both cases and controls; (4) Enrolled patients with PCa confirmed by histopathological examination, and controls with no history of neoplasms. Meanwhile, the exclusive criteria were as follows: (1) No case-control study; (2) Duplicate or unavailable data; (3) Studies not related to 8q24 or prostate cancer.

Data extraction
---------------

All available data from the eligible studies identified were extracted independently by two investigators (Li R and Qin ZQ). If any disagreement appeared, a third investigator (Tang JY) would join in and make a better decision. All the extracted data were recorded in a unified form and the following items were collected: first author\' name, publication year, ethnicity, source of controls, genotypic method, the number of cases and controls, the number of 8q24 polymorphisms carriers and non-carriers respectively and the results of the Hardy-Weinberg equilibrium (HWE) test.

Statistical analysis
--------------------

The Pearson\'s goodness-of-fit chi-square test was adopted to access HWE in the control groups. Besides, *P* value was more than 0.05, which was regarded as significant equilibrium. The strength of associations between 8q24 polymorphisms and susceptibility to PCa were evaluated by the pooled odds ratios (ORs) with 95% confidence intervals (CIs) using five genetic comparison models: allele model, homozygous model, heterozygous model, dominant model and recessive model. Fixed effect model (a Mantel-Haenszel method) and random effect model (a DerSimonian-Laird method), as two common statistical models, were selected according to Cochrane Q test and Higgins I^2^ statistic. If the heterogeneity is acceptable (I^2^ \< 50% suggested no obvious heterogeneity), the fixed effect model will be adopted; Otherwise, the random effect model will be performed to calculate the pooled ORs. Besides, the random effect model is a kind of method for disposing heterogeneous data, but it cannot replace the reason analysis of the source of heterogeneity. Normally, several reasons might induce the heterogeneity, including design scheme, measuring method, age, ethnicity and so on. In addition, subgroup analysis according to ethnicity, source of controls and genotypic method was further used to explore the source of heterogeneity. To examine the stability and reliability of the results in this meta-analysis, sensitive analysis was adopted to recalculate the pooled ORs following the sequential exclusion of a single study at a time. Moreover, Begg\'s funnel plots and Egger\'s linear regression test were used to check out the publication bias between all included studies, and *P* values were considered as a significantly selective bias when less than 0.05. STATA 12.0 software (State Corporation, College Station, TX, USA) was utilized to dispose all above statistical analyses.

Results
=======

Studies characteristics
-----------------------

Based on the retrieve strategy above, a total of related 182 articles were initially collected by a primary search of databases and reference lists. According to the inclusive criteria, 39 articles consisting of 80 studies were ultimately adopted in the present meta-analysis for a further evaluation, which had been accrued between March 2007 and January 2015 [@B4]-[@B6], [@B18]-[@B53]. The details of the literature search and screening process were shown in **Figure [1](#F1){ref-type="fig"}**. Among the eligible 80 studies, the distribution of genotypes in the controls was consistent with HWE, except three studies. In this meta-analysis, all of the baseline characteristics of the studies associated with the risk of PCa were listed in **Table [1](#T1){ref-type="table"}**. These studies were conducted in Caucasians, Asians, Africans and Mixed. Furthermore, in order to distinguish between different sources of control group, investigators divided them into population-based group or hospital-based group in all studies. Besides, six genotypic methods were applied in these studies, such as Taqman, PCR-RFLP, iPLEX and so on.

Quantitative synthesis results
------------------------------

In general, the pooled ORs and 95% CIs were utilized to evaluate the strength of the association between 8q24 polymorphisms and PCa risk based on five genetic comparison models. Results of the association between 8q24 polymorphisms and PCa susceptibility were listed in **Table [2](#T2){ref-type="table"}**. To explore the heterogeneity of these studies, stratification analysis by ethnicity, source of controls and genotypic method was conducted. Meanwhile, subgroups with less than three studies were excluded from further analysis to avoid the possible false associations.

Rs6983267 T\>G and PCa risk
---------------------------

Twenty-seven studies that met the inclusion criteria were retrieved, including 21,351 PCa cases and 17,190 controls. The pooled risk estimates indicated the significant association between rs6983267 T\>G and PCa susceptibility under *allele model* (OR=1.14, 95% CI=1.06-1.22), *dominant model* (OR=1.18, 95% CI=1.06-1.30), *heterozygous model* (OR=1.13, 95% CI=1.03-1.23), *homozygous model* (OR=1.31, 95% CI=1.13-1.51) and *recessive model* (OR=1.21, 95% CI=1.10-1.34) (**Figure [2](#F2){ref-type="fig"}**). Furthermore, when stratified by ethnicity, the results were significant in both Caucasians and Asians. In the subgroup by source of control, the results were significant in both population-based controls and hospital-based controls. In addition, stratification analysis by genotypic method showed the significant association with PCa risk only in TaqMan under all genetic models, while no significant association was found using PCR-RFLP and iPLEX method.

Rs1447295 C\>A and PCa risk
---------------------------

The current meta-analysis includes 22,142 PCa cases and 22,294 controls from a total of twenty-seven case-control studies on rs1447295 C\>A polymorphism and PCa risk. The pooled ORs of these studies were 1.25 (95% CI: 1.13-1.39) for *allele model*, 1.29 (95% CI: 1.14-1.45) for *dominant model*, 1.27 (95% CI: 1.13-1.43) for *homozygote model*, 1.40 (95% CI: 1.07-1.82) for *heterozygote model* and 1.36 (95% CI: 1.09-1.69) for *recessive model*, which indicated a strong association between rs1447295 mutation and the susceptibility to PCa (**Figure [3](#F3){ref-type="fig"}**). Moreover, in the subgroup by ethnicity, significant associations were observed in Asian population and Caucasian population. For the subgroup by source of control, the result was significant only in population-based controls under all genetic models, while no significant result was found in hospital-based controls. The significant association was more prominent among these studies using iPLEX than TaqMan under most of genetic models (e.g. iPLEX with *allele model* (OR=1.52, 95% CI=1.08-2.14); *dominant model* (OR=1.59, 95% CI=1.13-2.24); and *heterogeneity model* (OR=1.54, 95% CI=1.13-2.10) vs. TaqMan with *allele model* (OR=1.25, 95% CI=1.11-1.40); *dominant model* (OR=1.31, 95% CI=1.16-1.48); and *heterogeneity model* (OR=1.31, 95% CI=1.17-1.48).

Rs16901979 C\>A and PCa risk
----------------------------

Significant differences were found between rs16901979 C\>A polymorphism and susceptibility of PCa under *allele model* (OR=1.30, 95% CI=1.20-1.40), *dominant model* (OR=1.42, 95% CI=1.27-1.58), *heterozygous model* (OR=1.36, 95% CI=1.21-1.52), *homozygous model* (OR=1.64, 95% CI=1.39-1.92), *recessive model* (OR=1.36, 95% CI=1.18-1.57) (**Figure [4](#F4){ref-type="fig"}**). In the stratification analysis by ethnicity, the significant PCa risk effects were observed in African, Asian, Caucasian population under all genetic models. Besides, when stratified by source of control, the positive results were detected in population-based controls and hospital-based controls. In addition, in the subgroup analysis by genotypic method, the results of studies were significant in TaqMan and iPLEX rather than Illumina 1M chip and PCR-RFLP.

Rs6983561 A\>C and PCa risk
---------------------------

Seven studies that met the inclusion criteria were retrieved, including 2,666 PCa cases and 2,855 controls. Significant association between rs6983561 A\>C and PCa risk was observed by the pooled risk estimates under *allele model* (OR=1.41, 95% CI=1.27-1.57),*dominant model* (OR=1.50, 95% CI=1.31-1.71), *heterozygous model* (OR=1.42, 95% CI=1.23-1.63), *homozygous model* (OR=1.93, 95% CI=1.50-2.49) and *recessive model* (OR=1.64, 95% CI=1.30-2.08) (**Figure [5](#F5){ref-type="fig"}**). For subgroups by ethnicity, the results of these studies in Asians indicated the significant association with PCa risk under all genetic models. Similarly, stratified analysis by source of control detected a significant association in both population-based controls and hospital-based controls. Moreover, since all of the study number less than three for genotypic method, further analysis is not necessary.

Rs10090154 C\>T and PCa risk
----------------------------

The pooled risk estimates indicated the significant association between rs10090154 C\>T and the risk of PCa under *allele model* (OR=1.46, 95% CI=1.28-1.67), *dominant model* (OR=1.62, 95% CI=1.40-1.88), *heterozygous model* (OR=1.66, 95% CI=1.42-1.93). However, no significant association was found under *homozygous model* (OR=1.18, 95% CI=0.72-1.93), *recessive model* (OR=1.02, 95% CI=0.62-1.66) (**Figure [6](#F6){ref-type="fig"}**). Stratification analyses by ethnicity also detected that rs10090154 polymorphism increased PCa risk in Asians and Caucasians. Besides, increased PCa susceptibility associated with rs10090154 was observed only in population-based studies. Stratification analyses by genotypic method found that the meta-analysis results were significant in TaqMan, PCR-RFLP and iPLEX method, instead of PCR-HRM.

Sensitivity analysis
--------------------

Individual studies were consecutively omitted in the sensitivity analysis to detect the influence of each study on the pooled OR. The sensitivity analysis for the results of 8q24 genetic polymorphisms and PCa risk demonstrated that the obtained results were statistically robust and no individual study affected the pooled OR significantly (**Figure [7](#F7){ref-type="fig"}**).

Publication bias
----------------

The Begg\'s funnel plot and Egger\'s test were adopted to evaluate the publication bias of articles in this meta-analysis. As illustrated in **Figure [8](#F8){ref-type="fig"}**, the shapes of funnel plot were symmetric, suggesting that there was no evidence of publication bias under dominant model in this meta-analysis. Therefore, our results were reliable according to the included articles.

Discussion
==========

Chromosomal region 8q24 is a risk locus for a wide spectrum of cancers, and it is a risk region for PCa which has been investigated extensively. On the basis of racial differences and the fine-mapping study, 8q24 region contains at least three independent risk regions for PCa. Region 1 (126.54-128.62 Mb) was initially identified through a study of Icelandic families, which indicated that this region might confer risk of PCa and contribute to a higher incidence of PCa in Africa-American men than men of European ancestry [@B14]. Region 2 (128.14-128.28 Mb) contains a 14-SNP haplotype that efficiently tags a relatively uncommon (2-4%) susceptibility variant in individuals of European descent, which happens to be very common (42%) in Africa-American [@B54]. And region 3 (128.47-128.54 Mb) is defined as a recombination hot-spot among European Americans [@B47], [@B55]. Moreover, 8q24 is considered as a gene-free region, flanked by the FAM84B and MYC genes on the centromeric and telomeric ends respectively [@B55]. Though its biological significance in PCa is still unclear, some evidence in vitro and vivo experiments indicated that risk loci at 8q24 might be tissue-specific enhancers of MYC [@B15]. Especially, rs6983267 represents Region 1/Block 4 at 8q24 could be associated with MYC expression and CARLo-5, one of the long noncoding RNAs (CARLos) in the 8q24 region, is significantly related to the rs6983267 allele associated with increased cancer susceptibility [@B56]. However, their association with MYC expression in PCa is not conclusive and others failed to find clear association between rs6983267 genotype and MYC expression. Hence, more significant studies should be conducted to explore the function of these risk loci in the development of PCa.

Although previous meta-analysis has explored the associations between these 8q24 polymorphisms and PCa risk, we conducted a more detailed analysis with a larger sample size that included the most up-to-date research. To the best of our knowledge, this is the largest meta-analysis containing 80 studies to investigate associations between the selected 8q24 polymorphisms and PCa risk. During the past few years, many case-control studies have demonstrated the strong associations of 8q24 polymorphisms with the susceptibility to PCa. Nevertheless, the findings were controversial [@B2],[@B4]-[@B6]. For example, no significant association between rs6983267 polymorphism at 8q24 and PCa risk was found reported by Ren et al. [@B57]. However, Li *et al.* suggested that there is a significant PCa risk associated with the rs6983267 polymorphism at 8q24 [@B16]. As a powerful tool, meta-analysis was performed to provide a more comprehensive understanding of such associations compared to a single study, especially in analyzing unexplained studies. We took advantages of meta-analysis to prove the associations between 8q24 polymorphisms with PCa. According to quantitative synthesis results, all selected 8q24 polymorphisms (rs6983267 T\>G, rs1447295 C\>A, rs16901979 C\>A, rs6983561 A\>C and rs10090154 C\>T) were found significant associations with PCa risk under the most assumed genetic models in this meta-analysis.

When stratified by ethnicity, significant association was found between all selected risk loci and PCa risk in Asians. Studies in Caucasians found significant association between rs6983267 T\>G and rs1447295 C\>A polymorphisms and PCa risk. Meanwhile, significant association between the rs16901979 C\>A polymorphism and PCa risk was found in Africans, but as for rs1447295 C\>A, the result is contrary, which is consistent with the results as reported by Okobia *et al.* [@B58]. The ethnic-specific findings indicated that racial differences might have a relationship with the association between 8q24 polymorphisms and the susceptibility of PCa [@B59]. Though the exact mechanism was unclear, it was likely that different ethnic groups with various genetic backgrounds might have different gene polymorphisms risk in the development of PCa. The observation of highly variable PCa rates by ethnicities provided benefits to disease gene detection [@B60]. However, the related articles to explain these genetic differences were still scarce. More studies should be undertaken to investigate evolutionary and population genetics relationships across ethnicities.

In the subgroup analysis by source of controls, rs1447295 C\>A polymorphism showed significant association with PCa risk in the population-based control studies under all genetic models. While, no significant results were found in the hospital-based control studies under all genetic models. The possible reason might be that hospital-based controls might not have the similar representativeness of general populations. Meanwhile, when we selected the controls from hospitals, inherent selection biases might happen inevitably. Especially, the risk factors of PCa susceptibility were complex. Some ignored risk factors might interfere the results of this meta-analysis.

After stratified analysis by method of genotype, the significant results were observed in these studies using TaqMan method for all selected risk loci, while no significant results were found in these studies by PCR-RFLP method for rs6983267 T\>G, rs1447295 C\>A and rs16901979 C\>A polymorphisms. One possible reason for these discrepancies was that different genotypic methods had their own benefits in diverse aspects, which might lead to different statistical results. PCR-RFLP, as a traditional detecting technology of genetic polymorphisms, can only detect part of the SNP, which makes sequencing time-consuming and laborious. Besides, the two-level structure of DNA chain is also likely to cause artificial false and sequencing result deviation [@B61], [@B62]. However, the advantages of TaqMan are that since the reaction is carried out in the PCR process, the separation and elution process is not needed, thus reducing the possibility of PCR pollution [@B62]. Accordingly, only applying the same appropriate genotypic method would make the results more significant and reliable in the detection of the selected genetic polymorphisms.

To a certain extent, several limitations of this meta-analysis should be considered. (1) Some published studies involved in the 8q24 polymorphisms are not accord with the HWE, resulting in potential bias during control selection or genotypic errors; (2) The number of included studies in the stratified analyses was relatively small. Though we did not make further discussion in the subgroups with less than three studies to avoid the false associations, it might potentially also limit the enough statistical power to explore the real relationship; (3) Adjusted estimates could not be conducted in this meta-analysis. Due to inadequate information, we failed to adjust estimates by other covariates, such as age, obesity, smoking, lifestyle and so on; (4) PCa is a multifactorial disease and complex interactions between genetic and environment factors, which may affect the occurrence and development of PCa. The investigation of single gene region cannot interpret the association of PCa risk comprehensively. Therefore, more attention should be paid to interactions of SNP-SNP, gene-gene, and gene-environment in future large multicentric studies.

Conclusion
==========

In summary, the results of this meta-analysis suggested that five 8q24 polymorphisms (rs6983267 T\>G, rs1447295 C\>A, rs16901979 C\>A, rs6983561 A\>C and rs10090154 C\>T) had strong associations with the susceptibility to PCa. Therefore, the 8q24 polymorphisms might be considered the ideal markers in PCa diagnosis and therapy, which is worthy to exploring extensively in the subsequent studies. In addition, more high-quality and multicentric studies with larger sample sizes are needed to confirm these real associations.
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###### 

Characteristics of individual studies included in the meta-analysis.

  ---------------------- ------------------ ----------- ----- ------------------ ------- ---------- ------------ ------------ ------ ------- ------ ------ -----
  **rs6983267(T\>G)**                                                                    Case (n)                Control(n)                                
  Year                   Surname            Ethnicity   SOC   Genotypic          Case    Control    TT           TG           GG     TT      TG     GG     HWE
  2014                   Oskina             Caucasian   PB    TaqMan             389     341        89           186          114    77      177    87     Y
  2014                   Zhang              Asian       PB    PCR-RFLP           124     138        42           54           28     45      67     26     Y
  2014                   Francisco          Caucasian   HB    TaqMan             82      21         19           33           30     5       13     3      Y
  2013                   Chan               Asian       HB    Illumina 1M chip   288     144        89           136          63     47      74     23     Y
  2013                   Brankovie          Caucasian   HB    PCR-RFLP           150     100        53           80           17     25      49     26     Y
  2013                   Zhao               Asian       PB    PCR-RFLP           282     282        77           149          56     94      137    51     Y
  2012                   Ho                 Caucasian   PB    PCR-RFLP           216     248        70           104          42     66      136    46     Y
  2012                   Joung              Asian       HB    iPLEX              194     168        56           92           46     51      86     31     Y
  2012                   Liu                Asian       PB    PCR-RFLP           260     282        70           137          53     94      137    51     Y
  2011                   Okobia             African     HB    TaqMan             343     426        2            34           307    1       52     373    Y
  2011                   Papanikolopoulou   Caucasian   HB    TaqMan             86      99         16           46           24     39      47     13     Y
  2011                   Liu                Asian       PB    GWAS               792     1325       231          405          156    426     647    252    Y
  2011                   Liu                Asian       PB    PCR-RFLP           40      40         12           23           5      7       17     16     Y
  2010                   Zheng              Asian       PB    iPLEX              282     152        86           134          62     51      72     29     Y
  2009                   Liu                Asian       HB    TaqMan             391     323        151          181          59     147     151    25     Y
  2009                   Penney             Caucasian   PB    iPLEX              1305    1402       400          644          261    372     707    323    Y
  2009                   Penney             Caucasian   PB    iPLEX              3772    249        1184         1776         812    69      134    46     Y
  2009                   Beuten             Caucasian   PB    Illumina 1M chip   597     838        107          297          193    218     423    197    Y
  2008                   Terada             Asian       HB    PCR-RFLP           507     511        211          219          77     206     225    80     Y
  2008                   Salinas            Caucasian   PB    PCR-RFLP           1258    1238       242          652          364    308     617    313    Y
  2008                   Cheng              Caucasian   HB    TaqMan             417     417        76           215          126    106     206    105    Y
  2008                   Cheng              African     HB    TaqMan             89      89         1            14           74     4       11     74     N
  2008                   Wokolorczyk        Caucasian   PB    PCR-RFLP           1885    1910       385          942          558    513     977    420    Y
  2007                   Zheng              Caucasian   HB    iPLEX              1551    573        285          771          495    132     299    142    Y
  2007                   Yeager             Mixed       PB    GWAS               4296    4299       838          2104         1354   1072    2130   1097   Y
  2007                   Haiman             Caucasian   PB    TaqMan             1047    857        207          543          297    208     417    232    Y
  2007                   Haiman             Mixed       PB    TaqMan             708     718        290          310          108    335     300    83     Y
  **rs1447295C\>A**                                                                      Case (n)                Control(n)                                
  Year                   Surname            Ethnicity   SOC   Genotypic          Case    Control    CC           AC           AA     CC      AC     AA     HWE
  2014                   Zhang              Asian       PB    PCR-RFLP           123     137        74           45           4      91      44     2      Y
  2014                   Oskina             Caucasian   PB    TaqMan             392     343        291          93           8      292     50     1      Y
  2014                   Cheryl             African     PB    iPLEX              515     507        223          224          68     226     215    66     Y
  2014                   Francisco          Caucasian   HB    TaqMan             83      21         56           23           4      16      4      1      Y
  2013                   Chan               Asian       HB    Illumina 1M chip   289     143        180          92           17     94      44     5      Y
  2013                   Brankovie          Caucasian   HB    PCR-RFLP           150     100        86           61           3      11      82     7      N
  2013                   Zhao               Asian       PB    PCR-RFLP           277     287        161          108          8      197     86     4      Y
  2012                   Joung              Asian       HB    iPLEX              193     168        114          67           12     127     38     3      Y
  2012                   Liu                Asian       PB    PCR-RFLP           260     287        150          102          8      197     86     4      Y
  2011                   Okobia             African     HB    TaqMan             354     438        156          162          36     173     207    58     Y
  2011                   Zeegers            Caucasian   PB    TaqMan             281     267        224          53           4      196     64     7      Y
  2011                   Liu                Asian       PB    PCR-RFLP           40      40         11           7            22     5       15     20     Y
  2010                   Benford            African     HB    TaqMan             189     523        86           77           26     237     221    65     Y
  2010                   Wokolorczyk        Caucasian   HB    PCR-RFLP           690     602        515          156          19     484     115    3      Y
  2010                   Zheng              Asian       PB    iPLEX              284     151        173          96           15     110     35     6      Y
  2010                   Xie                Asian       PB    PCR-RFLP           120     120        74           41           5      90      26     4      Y
  2009                   Liu                Asian       HB    TaqMan             391     323        217          149          25     218     89     16     Y
  2009                   Chen               Asian       PB    TaqMan             340     337        215          119          6      253     75     9      Y
  2008                   Terada             Asian       HB    PCR-RFLP           507     387        310          172          25     254     122    11     Y
  2008                   Salinas            Caucasian   PB    TaqMan             1252    1233       937          288          27     994     225    14     Y
  2008                   Cheng              Caucasian   HB    TaqMan             417     417        318          97           2      344     69     4      Y
  2008                   Cheng              African     HB    TaqMan             89      89         39           44           6      43      35     11     Y
  2007                   Schumacher         Caucasian   PB    TaqMan             11466   12988      8462         2736         268    10344   2472   172    Y
  2007                   Zheng              Caucasian   HB    iPLEX              1546    571        1169         346          31     485     82     4      Y
  2007                   Suurinirmi         Caucasian   PB    TaqMan             582     538        435          136          11     427     107    4      Y
  2007                   Severi             Caucasian   PB    TaqMan             821     732        595          212          14     586     135    11     Y
  2007                   Wang               Caucasian   PB    TaqMan             491     545        383          99           9      439     101    5      Y
  **rs16901979(C\>A)**                                                                   Case (n)   Control(n)                                             
  Year                   Surname            Ethnicity   SOC   Genotypic          Case    Control    CC           AC           AA     CC      AC     AA     HWE
  2015                   Geraldine          African     PB    TaqMan             489     534        143          239          107    192     253    89     Y
  2014                   Cheryl             African     PB    iPLEX              520     510        123          270          127    154     236    120    Y
  2013                   Chan               Asian       HB    Illumina 1Mchip    289     144        139          119          31     64      68     12     Y
  2012                   Joung              Asian       HB    iPLEX              194     169        99           81           14     100     57     12     Y
  2011                   Okobia             African     HB    TaqMan             338     426        81           158          99     131     193    102    Y
  2010                   Chen               Asian       HB    TaqMan             331     335        148          148          35     173     138    24     Y
  2010                   Benford            African     HB    TaqMan             192     512        45           97           50     188     237    87     Y
  2010                   Xie                Asian       PB    PCR-RFLP           120     120        54           56           10     58      54     8      Y
  2010                   Zheng              Asian       PB    iPLEX              283     145        110          139          34     85      52     8      Y
  2008                   Cheng              Caucasian   HB    TaqMan             417     416        375          41           1      393     22     1      Y
  2008                   Cheng              African     HB    TaqMan             89      88         23           43           23     27      50     11     Y
  **rs6983561A\>C**                                                                      Case (n)   Control(n)                                             
  Year                   Surname            Ethnicity   SOC   Genotypic          Case    Control    AA           AC           CC     AA      AC     CC     HWE
  2014                   Hui                Asian       HB    PCR-HRM            276     283        139          108          29     156     110    17     Y
  2012                   Zhang              Asian       PB    PCR-HRM            212     231        110          80           22     130     87     14     Y
  2010                   Benford            African     HB    TaqMan             186     508        48           88           50     171     232    105    Y
  2010                   Chen               Asian       PB    TaqMan             324     336        135          152          37     175     136    25     Y
  2010                   Xie                Asian       PB    PCR-RFLP           120     120        56           53           11     62      50     8      Y
  2010                   Zheng              Asian       PB    iPLEX              284     141        109          141          34     80      53     8      Y
  2008                   Salinas            Caucasian   PB    PCR-RFLP           1264    1236       1124         135          5      1156    78     2      Y
  **rs10090154C\>T**                                                                     Case (n)   Control(n)                                             
  Year                   Surname            Ethnicity   SOC   Genotypic          Case    Control    CC           CT           TT     CC      CT     TT     HWE
  2014                   Oskina             Caucasian   PB    TaqMan             368     314        289          73           6      280     33     1      Y
  2014                   Zhang              Asian       PB    PCR-RFLP           123     131        74           48           1      90      39     2      Y
  2013                   Zhao               Asian       PB    PCR-RFLP           279     280        168          106          5      203     73     4      Y
  2011                   Pu                 Asian       PB    PCR-HRM            123     96         74           48           1      63      32     1      Y
  2010                   Benford            African     HB    TaqMan             189     505        124          59           6      357     131    17     Y
  2010                   Zheng              Asian       PB    iPLEX              282     148        170          98           14     112     30     6      N
  2008                   Cheng              Caucasian   PB    TaqMan             417     414        315          101          1      342     68     4      Y
  2008                   Cheng              African     PB    TaqMan             89      88         52           36           1      61      24     3      Y
  ---------------------- ------------------ ----------- ----- ------------------ ------- ---------- ------------ ------------ ------ ------- ------ ------ -----

SOC: Source of controls; PB: Population-based controls; HB: Hospital-based controls.

###### 

Meta-analysis results for the included studies of the association between 8q24 polymorphisms (rs6983267 T\>G, rs1447295 C\>A, rs16901979 C\>A, rs6983561 A\>C and rs10090154 C\>T) and risk of prostate cancer.

  Variables               No. of studies   Allele model            Dominant model   Heterozygous model   Homozygous model        Recessive model                                                                                                                                          
  ----------------------- ---------------- ----------------------- ---------------- -------------------- ----------------------- ----------------- ------- ----------------------- --------- ------- ------------------------ --------- ------- ----------------------- --------- ------- --
  ***rs6983267 T\>G***                     G vs T                  (TG+GG) vs TT    TG vs TT             GG vs TT                GG vs (TG+TT)                                                                                                                                            
  All                     27               **1.14 (1.06, 1.22)**   \<0.001          73.7                 **1.18 (1.06, 1.30)**   \<0.001           66.4    **1.13 (1.03, 1.23)**   0.002     49.9    **1.31 (1.13, 1.51)**    \<0.001   73.9    **1.21 (1.10, 1.34)**   \<0.001   64.4    
  Ethnicity                                                                                                                                                                                                                                                                               
  Caucasian               13               **1.14 (1.01, 1.28)**   \<0.001          83.9                 1.17 (0.98, 1.39)       \<0.001           80.1    1.11 (0.96, 1.30)       \<0.001   70.5    **1.31 (1.03, 1.65)**    \<0.001   83.7    **1.21 (1.03, 1.42)**   \<0.001   76.1    
  Asian                   10               **1.11 (1.00, 1.22)**   0.091            39.9                 **1.13 (1.02, 1.26)**   0.566             \<0.1   1.10 (0.99, 1.23)       0.829     \<0.1   **1.24 (1.00, 1.54)**    0.063     44.4    1.17 (0.96, 1.43)       0.041     48.7    
  African                 2                1.17 (0.81, 1.68)       0.910            \<0.1                1.35 (0.14, 13.32)      0.161             49.0    1.32 (0.09, 19.48)      0.111     60.7    1.35 (0.15, 12.50)       0.173     46.2    1.16 (0.78, 1.71)       0.677     \<0.1   
  Mixed                   2                **1.25 (1.19, 1.33)**   0.789            \<0.1                **1.35 (1.23, 1.48)**   0.482             \<0.1   **1.25 (1.13, 1.38)**   0.653     \<0.1   **1.57 (1.40, 1.76)**    0.782     \<0.1   **1.35 (1.23, 1.47)**   0.880     \<0.1   
  Source of control                                                                                                                                                                                                                                                                       
  PB                      16               **1.12 (1.03, 1.21)**   \<0.001          78.3                 **1.16 (1.03, 1.31)**   \<0.001           73.3    **1.13 (1.02, 1.25)**   0.001     60.2    **1.27 (1.08, 1.49)**    \<0.001   77.2    **1.18 (1.06, 1.32)**   \<0.001   66.8    
  HB                      11               **1.18 (1.02, 1.37)**   0.001            66.1                 1.20 (0.99, 1.47)       0.021             52.3    1.12 (0.95, 1.32)       0.179     27.9    **1.44 (1.02, 2.03)**    \<0.001   70.1    **1.29 (1.02, 1.64)**   0.002     63.2    
  Method of genotype                                                                                                                                                                                                                                                                      
  TaqMan                  9                **1.24 (1.12, 1.36)**   0.193            28.3                 **1.32 (1.13, 1.53)**   0.215             25.8    **1.23 (1.05, 1.45)**   0.209     26.4    **1.61 (1.26, 2.05)**    0.076     43.7    **1.34 (1.12, 1.59)**   0.099     40.2    
  PCR-RFLP                9                1.02 (0.88, 1.19)       \<0.001          79.1                 1.09 (0.90, 1.32)       0.001             68.7    1.11 (0.95, 1.30)       0.060     46.5    1.05 (0.78, 1.43)        \<0.001   78.8    1.02 (0.81, 1.29)       \<0.001   74.2    
  Illumina 1M chip        2                **1.34 (1.14, 1.57)**   0.262            20.7                 1.37 (0.94, 2.01)       0.121             58.3    1.23 (0.85, 1.78)       0.151     51.5    **1.87 (1.42, 2.45)**    0.345     \<0.1   **1.54 (1.24, 1.91)**   0.855     \<0.1   
  iPLEX                   5                1.06 (0.89, 1.27)       \<0.001          80.1                 1.01 (0.80, 1.27)       0.012             69.0    0.95 (0.79, 1.13)       0.130     43.8    1.14 (0.80, 1.63)        0.001     79.5    1.16 (0.89, 1.52)       0.004     73.5    
  GWAS                    2                **1.18 (1.01, 1.37)**   0.028            79.2                 **1.28 (1.08, 1.51)**   0.115             59.8    **1.24 (1.13, 1.36)**   0.441     \<0.1   **1.37 (1.00, 1.88)**    0.025     80.2    1.21 (0.95, 1.54)       0.041     76.0    
  ***rs1447295 c\>A***                     A vs C                  (AC+AA) vs CC    AC vs CC             AA vs CC                AA vs (AC+CC)                                                                                                                                            
  All                     27               **1.25 (1.13, 1.39)**   \<0.001          78.6                 **1.29 (1.14, 1.45)**   \<0.001           77.5    **1.27 (1.13, 1.43)**   \<0.001   75.9    **1.40 (1.07, 1.82)**    \<0.001   62.1    **1.36 (1.09, 1.69)**   0.005     46.5    
  Ethnicity                                                                                                                                                                                                                                                                               
  Asian                   11               **1.42 (1.29, 1.57)**   0.464            \<0.1                **1.52 (1.32, 1.76)**   0.163             29.7    **1.49 (1.26, 1.76)**   0.058     43.9    **1.64 (1.21, 2.23)**    0.510     \<0.1   **1.51 (1.12, 2.03)**   0.817     \<0.1   
  Caucasian               12               **1.23 (1.03, 1.46)**   \<0.001          86.0                 **1.22 (1.01, 1.49)**   \<0.001           85.9    1.20 (0.99, 1.46)       \<0.001   84.8    1.52 (0.92, 2.50)        \<0.001   69.3    **1.61 (1.10, 2.36)**   0.036     47.0    
  African                 4                0.97 (0.86, 1.08)       0.508            \<0.1                0.97 (0.83, 1.14)       0.549             \<0.1   0.99 (0.84, 1.17)       0.545     \<0.1   0.91 (0.71, 1.17)        0.401     \<0.1   0.92 (0.72, 1.17)       0.383     1.9     
  Source of control                                                                                                                                                                                                                                                                       
  PB                      15               **1.32 (1.20, 1.45)**   0.005            55.3                 **1.37 (1.23, 1.54)**   0.004             55.8    **1.36 (1.21, 1.52)**   0.004     56.1    **1.52 (1.16, 1.99)**    0.083     35.8    **1.46 (1.17, 1.83)**   0.211     21.8    
  HB                      12               1.16 (0.91, 1.47)       \<0.001          86.7                 1.13 (0.85, 1.51)       \<0.001           86.5    1.12 (0.84, 1.49)       \<0.001   85.1    1.25 (0.74, 2.08)        \<0.001   73.1    1.27 (0.85, 1.90)       0.006     57.8    
  Method of genotype                                                                                                                                                                                                                                                                      
  PCR-RFLP                8                1.11 (0.79, 1.56)       \<0.001          87.5                 0.98 (0.63, 1.53)       \<0.001           88.9    0.93 (0.59, 1.46)       \<0.001   88.7    1.33 (0.55, 3.18)        \<0.001   75.9    1.63 (0.97, 2.75)       0.112     40.1    
  TaqMan                  14               **1.25 (1.11, 1.40)**   \<0.001          70.7                 **1.31 (1.16, 1.48)**   \<0.001           64.4    **1.31 (1.17, 1.48)**   0.002     59.4    1.27 (0.92, 1.75)        0.003     58.4    1.20 (0.89, 1.62)       0.006     55.3    
  iPLEX                   4                **1.52 (1.08, 2.14)**   \<0.001          83.5                 **1.59 (1.13, 2.24)**   0.005             76.6    **1.54 (1.13, 2.10)**   0.021     69.3    1.89 (0.94, 3.79)        0.052     61.2    1.64 (0.88, 3.06)       0.092     53.4    
  Illumina 1M chip        1                1.20 (0.84, 1.71)       \-               \-                   1.16 (0.76, 1.77)       \-                \-      1.09 (0.71, 1.69)       \-        \-      1.78 (0.64, 4.96)        \-        \-      1.73 (0.62, 4.77)       \-        \-      
  ***rs16901979 C\>A***                    A vs C                  (AC+AA) vs CC    AC vs CC             AA vs CC                AA vs (AC+CC)                                                                                                                                            
  All                     11               **1.30 (1.20, 1.40)**   0.117            35.3                 **1.42 (1.27, 1.58)**   0.125             34.2    **1.36 (1.21, 1.52)**   0.147     31.5    **1.64 (1.39, 1.92)**    0.519     \<0.1   **1.36 (1.18, 1.57)**   0.514     \<0.1   
  Ethnicity                                                                                                                                                                                                                                                                               
  African                 5                **1.29 (1.17, 1.42)**   0.351            9.7                  **1.45 (1.25, 1.68)**   0.661             \<0.1   **1.37 (1.17, 1.60)**   0.674     \<0.1   **1.64 (1.36, 1.97 )**   0.314     15.8    **1.33 (1.14, 1.56)**   0.158     39.4    
  Asian                   5                **1.27 (1.11, 1.46)**   0.057            56.3                 **1.33 (1.12, 1.58)**   0.027             63.6    **1.28 (1.06, 1.53)**   0.040     60.2    **1.65 (1.19, 2.29)**    0.367     7.0     **1.48 (1.07, 2.03)**   0.679     \<0.1   
  Caucasian               1                **1.83 (1.10, 3.04)**   \-               \-                   **1.91 (1.13, 3.24)**   \-                \-      **1.95 (1.14, 3.34)**   \-        \-      1.05 (0.07, 16.82)       \-        \-      1.00 (0.06, 16.00)      \-        \-      
  Source of control                                                                                                                                                                                                                                                                       
  PB                                       **1.28 (1.14, 1.42)**   0.066            58.3                 **1.46 (1.24, 1.72)**   0.144             44.5    **1.41 (1.19, 1.68)**   0.220     32.1    **1.57 (1.25, 1.97)**    0.245     27.8    **1.26 (1.03, 1.54)**   0.230     30.3    
  HB                                       **1.31 (1.18, 1.46)**   0.232            25.8                 **1.39 (1.20, 1.61)**   0.144             37.3    **1.31 (1.12, 1.53)**   0.136     38.4    **1.71 (1.36, 2.15)**    0.595     \<0.1   **1.47 (1.20, 1.80)**   0.726     \<0.1   
  Method of genotype                                                                                                                                                                                                                                                                      
  TaqMan                  6                **1.35 (1.22, 1.49)**   0.551            \<0.1                **1.46 (1.27, 1.69)**   0.585             \<0.1   **1.37 (1.17, 1.59)**   0.518     \<0.1   **1.77 (1.44, 2.18)**    0.724     \<0.1   **1.49 (1.24, 1.78)**   0.729     \<0.1   
  iPLEX                   3                **1.29 (1.12, 1.48)**   0.033            70.6                 **1.56 (1.28, 1.91)**   0.146             48.0    **1.57 (1.27, 1.94)**   0.346     5.9     **1.50 (1.12, 2.01)**    0.114     53.9    1.15 (0.90, 1.48)       0.172     43.2    
  Illumina 1M chip        1                0.97 (0.72, 1.32)       \-               \-                   0.86 (0.58, 1.29)       \-                \-      0.81 (0.53, 1.23)       \-        \-      1.19 (0.57, 2.47)        \-        \-      1.32 (0.66, 2.66)       \-        \-      
  PCR-RFLP                1                1.13 (0.76, 1.66)       \-               \-                   1.14 (0.69, 1.90)       \-                \-      1.11 (0.66, 1.89)       \-        \-      1.34 (0.49, 3.65)        \-        \-      1.27 (0.48, 3.34)       \-        \-      
  ***rs6983561 A\>C***                     C vs A                  (AC+CC) vs AA    AC vs AA             CC vs AA                CC vs (AC+AA)                                                                                                                                            
  All                     7                **1.41 (1.27, 1.57)**   0.311            15.6                 **1.50 (1.31, 1.71)**   0.248             23.7    **1.42 (1.23, 1.63)**   0.186     31.7    **1.93 (1.50, 2.49)**    0.923     \<0.1   **1.64 (1.30, 2.08)**   0.943     \<0.1   
  Ethnicity                                                                                                                                                                                                                                                                               
  Asian                   5                **1.37 (1.21, 1.56)**   0.406            \<0.1                **1.41 (1.20, 1.67)**   0.216             30.9    **1.32 (1.11, 1.57)**   0.225     29.5    **2.02 (1.48, 2.76)**    0.826     \<0.1   **1.77 (1.30, 2.39)**   0.948     \<0.1   
  African                 1                **1.33 (1.05, 1.68)**   \-               \-                   **1.46 (1.00, 2.13)**   \-                \-      1.35 (0.90, 2.02)       \-        \-      **1.70 (1.07, 2.70)**    \-        \-      1.41 (0.96, 2.08)       \-        \-      
  Caucasian               1                **1.77 (1.34, 2.34)**   \-               \-                   **1.80 (1.35, 2.40)**   \-                \-      **1.78 (1.33, 2.38)**   \-        \-      2.57 (0.50, 13.28)       \-        \-      2.45 (0.47, 12.65)      \-        \-      
  Source of control                                                                                                                                                                                                                                                                       
  PB                      5                **1.48 (1.30, 1.69)**   0.227            29.3                 **1.58 (1.35, 1.85)**   0.208             32.0    **1.51 (1.28, 1.78)**   0.184     35.6    **2.07 (1.46, 2.94)**    0.816     \<0.1   **1.77 (1.26, 2.49)**   0.930     \<0.1   
  HB                      2                **1.30 (1.09, 1.55)**   0.776            \<0.1                **1.32 (1.03, 1.69)**   0.467             \<0.1   1.20 (0.92, 2.57)       0.454     \<0.1   **1.77 (1.22, 2.58)**    0.765     \<0.1   **1.53 (1.10, 2.12)**   0.481     \<0.1   
  Method of genotype                                                                                                                                                                                                                                                                      
  PCR-HRM                 2                **1.25 (1.03, 1.53)**   0.959            \<0.1                1.20 (0.94, 1.54)       0.955             \<0.1   1.10 (0.84, 1.42)       0.959     \<0.1   **1.89 (1.17, 3.05)**    0.951     \<0.1   **1.82 (1.14, 2.89)**   0.961     \<0.1   
  TaqMan                  2                **1.36 (1.15, 1.61)**   0.755            \<0.1                **1.50 (1.18, 1.90)**   0.865             \<0.1   **1.41 (1.10, 1.81)**   0.791     \<0.1   **1.79 (1.25, 2.55)**    0.739     \<0.1   **1.48 (1.08, 2.02)**   0.703     \<0.1   
  PCR-RFLP                2                **1.56 (1.25, 1.96)**   0.110            60.8                 **1.64 (1.28, 2.11)**   0.192             41.2    **1.62 (1.26, 2.09)**   0.176     45.4    1.76 (0.77, 4.07)        0.591     \<0.1   1.64 (0.73, 3.70)       0.569     \<0.1   
  iPLEX                   1                **1.80 (1.30, 2.48)**   \-               \-                   **2.11 (1.40, 3.17)**   \-                \-      **1.95 (1.27, 2.99)**   \-        \-      **3.12 (1.37, 7.10)**    \-        \-      **2.26 (1.02, 5.02)**   \-        \-      
  ***rs10090154 C\>T***                    T vs C                  (CT+TT) vs CC    CT vs CC             TT vs CC                TT vs (CT+CC)                                                                                                                                            
  All                     8                **1.46 (1.28, 1.67)**   0.342            11.4                 **1.62 (1.40, 1.88)**   0.502             \<0.1   **1.66 (1.42, 1.93)**   0.624     \<0.1   1.18 (0.72, 1.93)        0.585     \<0.1   1.02 (0.62, 1.66)       0.607     \<0.1   
  Ethnicity                                                                                                                                                                                                                                                                               
  Caucasian               2                **1.67 (1.30, 2.13)**   0.079            67.6                 **1.78 (1.37, 2.33)**   0.175             45.7    **1.80 (1.37, 2.36)**   0.320     \<0.1   1.43 (0.45, 4.57)        0.049     74.2    1.28 (0.40, 4.11)       0.050     73.9    
  Asian                   4                **1.48 (1.22, 1.80)**   0.592            \<0.1                **1.67 (1.34, 2.09)**   0.549             \<0.1   **1.70 (1.35, 2.13)**   0.529     \<0.1   1.35 (0.66, 2.76)        0.893     \<0.1   1.11 (0.55, 2.27)       0.917     \<0.1   
  African                 2                1.22 (0.93, 1.59)       0.728            \<0.1                1.34 (0.99, 1.83)       0.510             \<0.1   **1.40 (1.02, 1.93)**   0.415     \<0.1   0.87 (0.36, 2.08)        0.450     \<0.1   0.79 (0.33, 1.88)       0.394     \<0.1   
  Source of control                                                                                                                                                                                                                                                                       
  PB                      7                **1.53 (1.32, 1.78)**   0.449            \<0.1                **1.71 (1.45, 2.01)**   0.660             \<0.1   **1.74 (1.47, 2.06)**   0.769     \<0.1   1.24 (0.70, 2.22)        0.480     \<0.1   1.05 (0.59, 1.87)       0.492     \<0.1   
  HB                      1                1.18 (0.87, 1.61)       \-               \-                   1.26 (0.89, 1.81)       \-                \-      1.30 (0.90, 1.88)       \-        \-      1.02 (0.39, 2.63)        \-        \-      0.94 (0.37, 2.42)       \-        \-      
  Method of genotype                                                                                                                                                                                                                                                                      
  TaqMan                  4                **1.45 (1.21, 1.73)**   0.115            49.4                 **1.59 (1.30, 1.94)**   0.252             26.6    **1.63 (1.32, 2.00)**   0.391     \<0.1   1.04 (0.52, 2.06)        0.199     35.6    0.93 (0.47, 1.86)       0.190     37.0    
  PCR-RFLP                2                **1.47 (1.13, 1.89)**   0.525            \<0.1                **1.64 (1.23, 2.20)**   0.572             \<0.1   **1.67 (1.24, 2.24)**   0.624     \<0.1   1.21 (0.38, 3.80)        0.518     \<0.1   1.02 (0.33, 3.19)       0.537     \<0.1   
  PCR-HRM                 1                1.19 (0.73, 1.92)       \-               \-                   1.26 (0.73, 2.20)       \-                \-      1.28 (0.73, 2.23)       \-        \-      0.85 (0.05, 13.89)       \-        \-      0.78 (0.05, 12.61)      \-        \-      
  iPLEX                   1                **1.74 (1.19, 2.55)**   \-               \-                   **2.05 (1.31, 3.20)**   \-                \-      **2.15 (1.34, 3.46)**   \-        \-      1.54 (0.57, 4.12)        \-        \-      1.24 (0.47, 3.29)       \-        \-      
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